Human Lung Responses to Respiratory Pathogens
Primary Purpose
Respiratory Infection
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Vitamin D3 (cholecalciferol)
Placebo Sugar Pill
Sponsored by
About this trial
This is an interventional basic science trial for Respiratory Infection focused on measuring Vitamin D, Respiratory infection, Innate immunity
Eligibility Criteria
Inclusion Criteria:
Signed informed consent form Age 18 - 60 Healthy nonsmoker, healthy smoker Forced expiratory volume in 1 second (for smokers) > 60% predicted.
Exclusion Criteria:
- Pregnant or breastfeeding
- Medications (with the exception of hormonal birth control, thyroid medication or prespecified over the counter medications), including multi-vitamins and any preparation that contains vitamin D
- Asthma
- Heart disease
- Diabetes
- Previous positive tuberculin skin test, or previous diagnosis of tuberculosis
- Recent respiratory tract infection
- History of multiple bouts of pneumonia
- Allergies to caines, atropine, or a history of adverse reaction to narcotics
- Other factors that increase the risk of bronchoscopy
- Evidence of acute bronchitis within the past 2 weeks
Sites / Locations
- University of Iowa
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vitamin D3 (cholecalciferol)
Sugar capsule
Arm Description
Vitamin D3 (1000 international units) daily for 3 months.
Placebo comparator made of sugar in a capsule
Outcomes
Primary Outcome Measures
Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU)
We investigated the effect of vitamin D3 supplementation on airway surface liquid antimicrobial activity using a bioluminescent bacterial challenge. We challenged airway surface liquid samples with bioluminescent bacteria and measured live bacteria by relative light units (RLU) after 2 minutes as a surrogate of antimicrobial activity. We interpreted a reduction in live bacteria after challenge in relative light units as increased antimicrobial activity
Secondary Outcome Measures
Full Information
NCT ID
NCT01967628
First Posted
October 17, 2013
Last Updated
February 28, 2018
Sponsor
University of Iowa
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
1. Study Identification
Unique Protocol Identification Number
NCT01967628
Brief Title
Human Lung Responses to Respiratory Pathogens
Official Title
Human Lung Responses to Respiratory Pathogens
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
October 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Iowa
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
For most individuals, the lung has a remarkable ability to deal with exposure to a variety of inhaled bacteria. Some individuals, however, do have recurrent bacterial infections, usually in the form of acute or chronic bronchitis and, in some instances, pneumonia. The reasons for this variability in bacterial infections between otherwise healthy subjects, between types of lung disease, and within the same type of lung disease are poorly understood.
Variability in susceptibility to bacterial infections is partially explained by differences in exposure to infectious agents, genetic susceptibility and innate (or early) immune responses. It is of interest that the incidence and severity of bacterial infections is greatest during the winter months. Other than viral infections, there are few variables that change with season. Vitamin D is one known immune modulator with a seasonal periodicity. The hypothesis of this study is that levels of vitamin D are an important determinant of the innate defense of the lung against inhaled bacteria. The investigators further postulate that vitamin D has effects on the innate immune function of both alveolar macrophages and lung epithelial cells.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Infection
Keywords
Vitamin D, Respiratory infection, Innate immunity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
98 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D3 (cholecalciferol)
Arm Type
Experimental
Arm Description
Vitamin D3 (1000 international units) daily for 3 months.
Arm Title
Sugar capsule
Arm Type
Placebo Comparator
Arm Description
Placebo comparator made of sugar in a capsule
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3 (cholecalciferol)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Sugar Pill
Primary Outcome Measure Information:
Title
Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU)
Description
We investigated the effect of vitamin D3 supplementation on airway surface liquid antimicrobial activity using a bioluminescent bacterial challenge. We challenged airway surface liquid samples with bioluminescent bacteria and measured live bacteria by relative light units (RLU) after 2 minutes as a surrogate of antimicrobial activity. We interpreted a reduction in live bacteria after challenge in relative light units as increased antimicrobial activity
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Signed informed consent form Age 18 - 60 Healthy nonsmoker, healthy smoker Forced expiratory volume in 1 second (for smokers) > 60% predicted.
Exclusion Criteria:
Pregnant or breastfeeding
Medications (with the exception of hormonal birth control, thyroid medication or prespecified over the counter medications), including multi-vitamins and any preparation that contains vitamin D
Asthma
Heart disease
Diabetes
Previous positive tuberculin skin test, or previous diagnosis of tuberculosis
Recent respiratory tract infection
History of multiple bouts of pneumonia
Allergies to caines, atropine, or a history of adverse reaction to narcotics
Other factors that increase the risk of bronchoscopy
Evidence of acute bronchitis within the past 2 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alicia K Gerke, MD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
28883932
Citation
Vargas Buonfiglio LG, Cano M, Pezzulo AA, Vanegas Calderon OG, Zabner J, Gerke AK, Comellas AP. Effect of vitamin D3 on the antimicrobial activity of human airway surface liquid: preliminary results of a randomised placebo-controlled double-blind trial. BMJ Open Respir Res. 2017 Jun 4;4(1):e000211. doi: 10.1136/bmjresp-2017-000211. eCollection 2017.
Results Reference
derived
PubMed Identifier
24669961
Citation
Gerke AK, Pezzulo AA, Tang F, Cavanaugh JE, Bair TB, Phillips E, Powers LS, Monick MM. Effects of vitamin D supplementation on alveolar macrophage gene expression: preliminary results of a randomized, controlled trial. Multidiscip Respir Med. 2014 Mar 26;9(1):18. doi: 10.1186/2049-6958-9-18.
Results Reference
derived
Learn more about this trial
Human Lung Responses to Respiratory Pathogens
We'll reach out to this number within 24 hrs